Patents by Inventor Ninghan Feng

Ninghan Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12096919
    Abstract: Disclosed is an integrated urine anaerobic collection and culture apparatus, comprising: a catheter, at a front end of which a circular arc-shaped guide part and a first through hole are arranged, where a piston part is arranged inside the front end of the catheter; a first branch tube and a second branch tube, which are connected with the catheter, the first branch tube is connected with a first negative pressure vessel, and the first branch tube and the second branch tube are respectively provided with a first valve and a second valve; an aseptic centrifuge tube, which includes a tube body and a first cover body, where the first cover body is provided with a first check valve and a second check valve; a second negative pressure vessel. The present disclosure can realize the whole anaerobic operation of urine collection and culture in the bladder.
    Type: Grant
    Filed: April 1, 2024
    Date of Patent: September 24, 2024
    Assignee: NANJING MEDICAL UNIVERSITY
    Inventors: Ninghan Feng, Hao Lin, Zhenyi Xu, Yifan Tang, Fengping Liu
  • Publication number: 20240304007
    Abstract: This invention discloses a method and system for the segmentation and clustering of nuclei based on single-cell pathological images. The contour tracing method is used to calculate all the closed contours existing in the pathological tissue images; and optimizes the contours to obtain the segmented images of the nuclei. Then, according to the mask image corresponding to the segmented images of the nuclei, the segmented images of the nuclei are divided into individual nucleus images; the influencing features of the nuclei in the corresponding area are extracted through the mask image; through feature selection, redundant features are removed, and then the UMAP feature reduction method is used to select the two most important features for clustering the nuclei. By first segmenting and dividing the nucleus area in the pathological images, and then using the divided single nucleus for feature extraction, the basis for clustering is made more objective.
    Type: Application
    Filed: March 24, 2024
    Publication date: September 12, 2024
    Inventors: NINGHAN FENG, HONG TANG, GUANZHEN YU, YUEZHOU ZHANG, YANGKUN FENG, FENGPING LIU, YANG WANG, PENG JIANG
  • Patent number: 11911353
    Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: February 27, 2024
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Yongquan Chen, Hongyan Qu, Chunlei Tang, Guosheng Wu, Guozhen Cui, Ninghan Feng, Xiaoying Wang, Kai Shan, Shenglong Zhu, Lengyun Wei
  • Patent number: 11704808
    Abstract: A segmentation method for tumor regions in a pathological image of clear cell renal cell carcinoma based on deep learning includes data acquisition and pre-processing, building and training of a classification network SENet and prediction of tumor regions. The present invention studies clear cell renal cell carcinoma based on pathological images, yielding results with higher reliability than judgments made based on CT or MRI images. The present invention overcomes the drawback that the previous research on clear cell renal cell carcinoma is only limited to judgment on presence by being able to visually provide the position and size of tumor regions, which is convenient for the medical profession to better study the pathogenesis and directions to the treatment of clear cell renal cell carcinoma.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: July 18, 2023
    Assignee: WUXI SECOND PEOPLE'S HOSPITAL
    Inventors: Ninghan Feng, Hong Tang, Guanzhen Yu, Jinzhu Su, Yang Wang, Yangkun Feng, Peng Jiang
  • Publication number: 20210046027
    Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Inventors: Yongquan CHEN, Hongyan QU, Chunlei TANG, Guosheng WU, Guozhen CUI, Ninghan Feng, Xiaoying Wang, Kai SHAN, Shenglong ZHU, Lengyun WEI